TY - JOUR
T1 - Toll-like receptor alterations in myelodysplastic syndrome
AU - Wei, Y.
AU - Dimicoli, S.
AU - Bueso-Ramos, C.
AU - Chen, R.
AU - Yang, H.
AU - Neuberg, D.
AU - Pierce, S.
AU - Jia, Y.
AU - Zheng, H.
AU - Wang, H.
AU - Wang, X.
AU - Nguyen, M.
AU - Wang, S. A.
AU - Ebert, B.
AU - Bejar, R.
AU - Levine, R.
AU - Abdel-Wahab, O.
AU - Kleppe, M.
AU - Ganan-Gomez, I.
AU - Kantarjian, H.
AU - Garcia-Manero, G.
N1 - Funding Information:
This work was supported by grant RP100202 from the Cancer Prevention and Research Institute of Texas (CPRIT), the DOD/Congressionally Directed Medical Research Programs, the MD Anderson Cancer Center Leukemia SPORE grant CA100632, the Evans Foundation and the MD Anderson Cancer Center CCSG CA016672. IG-G was funded by the Regional Ministry of Education of Castilla-la Mancha, Spain, supported by the European Social Fund (ESF). We are thankful to Zhihong Fang, Ying Hu, and Michael Fernandez for their technical help.
PY - 2013/9
Y1 - 2013/9
N2 - Recent studies have implicated the innate immunity system in the pathogenesis of myelodysplastic syndromes (MDS). Toll-like receptor (TLR) genes encode key innate immunity signal initiators. We recently identified multiple genes, known to be regulated by TLRs, to be overexpressed in MDS bone marrow (BM) CD34+ cells, and hypothesized that TLR signaling is abnormally activated in MDS. We analyzed a large cohort of MDS cases and identified TLR1, TLR2 and TLR6 to be significantly overexpressed in MDS BM CD34+ cells. Deep sequencing followed by Sanger resequencing of TLR1, TLR2, TLR4 and TLR6 genes uncovered a recurrent genetic variant, TLR2-F217S, in 11% of 149 patients. Functionally, TLR2-F217S results in enhanced activation of downstream signaling including NF-κB activity after TLR2 agonist treatment. In cultured primary BM CD34+ cells of normal donors, TLR2 agonists induced histone demethylase JMJD3 and interleukin-8 gene expression. Inhibition of TLR2 in BM CD34+ cells from patients with lower-risk MDS using short hairpin RNA resulted in increased erythroid colony formation. Finally, RNA expression levels of TLR2 and TLR6, as well as presence of TLR2-F217S, are associated with distinct prognosis and clinical characteristics. These findings indicate that TLR2-centered signaling is deregulated in MDS, and that its targeting may have potential therapeutic benefit in MDS.
AB - Recent studies have implicated the innate immunity system in the pathogenesis of myelodysplastic syndromes (MDS). Toll-like receptor (TLR) genes encode key innate immunity signal initiators. We recently identified multiple genes, known to be regulated by TLRs, to be overexpressed in MDS bone marrow (BM) CD34+ cells, and hypothesized that TLR signaling is abnormally activated in MDS. We analyzed a large cohort of MDS cases and identified TLR1, TLR2 and TLR6 to be significantly overexpressed in MDS BM CD34+ cells. Deep sequencing followed by Sanger resequencing of TLR1, TLR2, TLR4 and TLR6 genes uncovered a recurrent genetic variant, TLR2-F217S, in 11% of 149 patients. Functionally, TLR2-F217S results in enhanced activation of downstream signaling including NF-κB activity after TLR2 agonist treatment. In cultured primary BM CD34+ cells of normal donors, TLR2 agonists induced histone demethylase JMJD3 and interleukin-8 gene expression. Inhibition of TLR2 in BM CD34+ cells from patients with lower-risk MDS using short hairpin RNA resulted in increased erythroid colony formation. Finally, RNA expression levels of TLR2 and TLR6, as well as presence of TLR2-F217S, are associated with distinct prognosis and clinical characteristics. These findings indicate that TLR2-centered signaling is deregulated in MDS, and that its targeting may have potential therapeutic benefit in MDS.
KW - IL-8
KW - JMJD3
KW - Toll-like receptor
KW - innate immunity
KW - myelodysplastic syndromes
UR - http://www.scopus.com/inward/record.url?scp=84883742414&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883742414&partnerID=8YFLogxK
U2 - 10.1038/leu.2013.180
DO - 10.1038/leu.2013.180
M3 - Article
C2 - 23765228
AN - SCOPUS:84883742414
SN - 0887-6924
VL - 27
SP - 1832
EP - 1840
JO - Leukemia
JF - Leukemia
IS - 9
ER -